Pharma BD Deal Intelligence
Bristol Myers Squibb will leverage Chai advanced AI models and platform capabilities, including its leading molecular folding and design models, to support the…
Independent trade press corroboration of the Chai Discovery / Bristol Myers Squibb AI antibody discovery collaboration announced in August 2026.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Chai Discovery, Inc. and Bristol Myers Squibb entered an AI-driven antibody discovery collaboration announced August 19, 2026. Bristol Myers Squibb will apply Chai Discovery's AI models and platform capabilities, including its molecular folding and design models, to discover therapeutic antibody candidates across its portfolio and to build an AI-powered discovery system intended to compress the timeline from concept to viable therapeutic candidate. The agreement is a platform/technology-access collaboration rather than an asset in-license; no specific disease areas were named and no financial terms (upfront, milestones or royalties) were disclosed by either party. The deal follows Chai Discovery's July 2026 collaboration with Novartis, making Bristol Myers Squibb its second announced large-pharma partner.
← Browse all deals · How we score deals
More: 2026 deals · Bristol Myers Squibb deals